Sequella CEO Carol Nacy On Partnering With Pfizer To Solve Multidrug-resistant TB
This article was originally published in PharmAsia News
Executive Summary
New drugs in development could help solve a looming global multidrug-resistant TB epidemic and anchor a new treatment regimen.
You may also be interested in...
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.
Under Industry Pressure, China Blinks On Restricting Use Of Anti-infectives - Or Does It?
SHANGHAI - China's State Council Aug. 4 released a formal draft of a new policy to address the abuse of anti-infectives and is soliciting public comments. Surprising analysts, the draft policy is less strict than a previous version that had circulated around industry, leaving the future of China's anti-infective market more difficult to predict
Novartis, AstraZeneca Pledge Support For Russia At St. Petersburg Economic Forum In Latest Big Pharma Move To Go Local
Russia Premier Vladimir Putin has said he wants multinational pharmaceutical companies to manufacture drugs in Russia and support development of the local industry as part of a $4 billion government initiative to reform the Russia healthcare market by 2020. So perhaps it is not too surprising that both Novartis AG and AstraZeneca PLC chose to re-emphasize their commitments to Russia by each issuing press releases June 16 to coincide with the kickoff of the St. Petersburg International Economic Forum